Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expands Aethlon Hemopurifier IDE To Address Ebola

This article was originally published in The Gray Sheet

Executive Summary

The agency approved an expanded clinical trial allowing Aethlon to test an Ebola treatment protocol at 10 U.S. sites; requires the company to gain institutional review board approval from each institution and the trials can only enroll up to 20 patients.

Advertisement

Related Content

FDA Emergency Authorizes Roche Ebola Assay
WHO Launches Initiatives For Ebola POC Tests

Topics

Advertisement
UsernamePublicRestriction

Register

MT033683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel